Sun Nuclear Acquires Oncospace, AI-Focused Radiation Oncology Software Provider
Oncospace's AI and machine-learning technologies are designed to develop data-driven, physician-centric solutions that optimize patient outcomes. Since its inception in 2018, Oncospace has launched two main offerings:
Gateway: A Treatment Planning Conversion solution for Philips Pinnacle users, which converts patient archives to modern treatment planning solutions, such as Raysearch Raystation and Varian Medical Systems® Eclipse. While originally developed for prostate treatments, this solution has since expanded to head and neck radiotherapy, with future offerings planned.
A Predictive Plan Quality and Feasibility solution, which leverages the AI approach of machine learning to analyze thousands of clinical treatment plans and derive achievable, best-practice dosimetry goals for plan optimization and evaluation.
'We are excited to welcome Oncospace into the Sun Nuclear family,' said Luis Rivera, Sun Nuclear president and Mirion Medical executive vice president. 'By incorporating the Oncospace solutions dependent on AI and machine-learning capabilities, Sun Nuclear is affirming our commitment to drive innovation in radiation therapy. We look forward to the positive impact this will have on our software roadmap.'
By informing actions through harnessing vital information, the Oncospace offerings address the demands of radiation oncology professionals while improving the precision and efficiency of radiation therapy planning, thus enhancing the overall quality of care and outcomes. This acquisition aligns with the Sun Nuclear focus of enhancing the quality and accessibility of radiation therapy, ensuring that patients receive the best possible treatment.
Oncospace software will be featured in Sun Nuclear's booth at ESTRO 2025, May 2-6, in Vienna, Austria. ESTRO is the annual congress for the European Society for Radiotherapy and Oncology and includes Europe's largest industry exhibition in radiation oncology.
About Sun Nuclear
Sun Nuclear is part of Mirion Medical, a group of healthcare-focused brands within Mirion , providing innovative solutions for Radiation Therapy and Diagnostic Imaging centers. More than 6,000 cancer centers worldwide rely on Sun Nuclear for independent, integrated Quality Management. With a focus on ongoing support, Sun Nuclear aims to ease technology adoption, enhance workflows and improve outcomes – so that healthcare providers can achieve real results for Patient Safety. Learn more: sunnuclear.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
CIBL, Inc. Reports Second Quarter Operating Results
RENO, Nev.--(BUSINESS WIRE)--CIBL, Inc. ('CIBL' or the 'Company'; OTC Pink ®: CIBY), a holding company with interests in broadband operations in New Hampshire, reported its financial results for the quarter ended June 30, 2025. Revenues increased 4.1% to $529,000 in the second quarter of 2025 from $508,000 in the second quarter 2024 Earnings per share were $5.60 per share in the second quarter of 2025 compared to a loss per share of $5.22 in the second quarter 2024 Cash and investments, net of zero debt, were $20,452 as of June 30, 2025 Christopher Nossokoff joined CIBL as a mergers and acquisitions advisor to provide and accelerate our interest in non-organic growth Results from Operations Three Months Ended June 30, 2025 Revenues increased 4.1% to $529,000 in the second quarter 2025 from $508,000 in the second quarter 2024 due to increased service revenues from broadband, end-user terminals and voice over internet protocol. EBITDA from operations 1 decreased 21.3% to $118,000 in the second quarter 2025 compared to $150,000 in the second quarter 2024 due to less capitalized labor for plant under construction and switch replacements. Six Months Ended June 30, 2025 Revenues increased 7.9% to $1,053,000 for the six months ended June 30, 2025 from $976,000 for the six months ended June 30, 2024 due to new services, one-time equipment revenues and system upgrades. EBITDA from operations 1 decreased 16.8% to $242,000 for the six months ended June 30, 2025 from $291,000 for the six months ended June 30, 2024 due to the increase in revenues discussed above partially offset by less capitalized labor for plant under construction and switch replacements. _______________ 1 A reconciliation of non-GAAP financial measures to the most comparable GAAP measure is provided at the end of this press release. Expand Other Highlights Capital expenditures were $45,000 and $164,000 for the six months ended June 30, 2025, and 2024, respectively. During the six months ended June 30, 2025, the Company acquired 725 of its shares at an average price of $1,690 per share. As of June 30, 2025, CIBL has 11,541 shares outstanding. Since its spin-off from LICT Corporation in 2007, CIBL has repurchased 15,325 of its shares for $21.8 million, or an average price of $1,420 per share. CIBL's Board of Directors continues to evaluate a broad range of strategic alternatives for the company to create shareholder value. About CIBL, Inc. CIBL is a holding company with interests in broadband operations. CIBL's operations consist of Bretton Woods Telephone Company and World Surfer, Inc. providers of broadband and communication services in Northern New Hampshire. CIBL is listed on OTC Pink® under the symbol CIBY and information can be obtained on our website: Cautionary Note Concerning Forward-Looking Statements To the extent this release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, it should be recognized that such information is based upon assumptions, projections and forecasts, including without limitation business conditions and financial markets, and the cautionary statements set forth in documents filed by CIBL on its website, Thus, such information is subject to uncertainties, risks and inaccuracies, which could be material, and there can be no assurance that such information will prove to be accurate. CIBL Inc. and Subsidiaries Attachment B Consolidated Balance Sheets (Unaudited) (USD in thousands, except share data) December 31, 2024 (Audited) June 30, 2024 Assets Current assets Cash and cash equivalents $ 1,594 $ 2,341 $ 1,348 Investments in United States Treasury Bills 16,550 16,598 18,841 Investment in available for sale equity securities 44 294 279 Investment in equity method limited partnership 1,706 1,645 1,595 Accounts receivable 253 284 221 Prepaid expenses 94 192 71 Materials and supplies 59 59 59 Income taxes receivable 37 - 43 Total current assets 20,337 21,413 22,457 Telecommunications, property, plant and equipment, net 907 958 771 Goodwill 337 337 337 Other intangibles, net 25 30 35 Other investments 1,708 1,636 700 Deferred income taxes 34 39 50 Other assets 59 59 71 Total assets $ 23,407 $ 24,472 $ 24,421 Liabilities Current liabilities Income taxes payable $ -- $ 14 $ -- Trade accounts payable and accrued expenses 142 138 124 Accrued liabilities 353 284 381 Total current liabilities 495 436 505 Other liabilities 46 46 59 Total liabilities 541 482 564 Equity Common stock, par value $.01, 30,000 shares authorized; 26,865, 26,865 and 26,415 issued; and 11,541, 12,266 and 12,399 outstanding -- -- -- Contributed capital 7,112 7,112 6,212 Retained earnings 37,545 37,416 37,147 Treasury stock, 15,325; 14,600; and 14,017 shares at cost (21,791 ) (20,538 ) (19,502 ) Total equity 22,866 23,990 23,857 Total liabilities and equity $ 23,407 $ 24,472 $ 24,421 Expand CIBL Inc. and Subsidiaries Attachment C EBTIDA Reconciliation (Unaudited) (USD in thousands, except share data) The following table is a reconciliation of EBITDA from operations to Net income (loss): Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net income (loss) $ 65 $ (65 ) $ 129 $ (126 ) Adjustments: Interest income (185 ) (266 ) (377 ) (521 ) Income tax expense (benefit) 20 (31 ) 34 (46 ) Depreciation and amortization 52 34 100 65 Total adjustments (113 ) (263 ) (243 ) (502 ) EBITDA (48 ) (328 ) (114 ) (628 ) Corporate office expenses 273 280 509 523 Equity in earnings of affiliated companies (107 ) 127 (133 ) 283 Unrealized and realized losses on available for sale equity securities - 71 (20 ) 113 EBITDA from operations $ 118 $ 150 $ 242 $ 291 Expand
Yahoo
4 hours ago
- Yahoo
Reejig Brings World-First Task-Level Intelligence to Galileo, Giving Leaders the Clarity to Reinvent Work for AI
Reejig's partnership with The Josh Bersin Company enables leaders to make data-driven AI transformation decisions, with visibility into exactly what work can be automated and how to redesign roles for the AI era. NEW YORK CITY, N.Y., Aug. 15, 2025 /PRNewswire/ -- Reejig, the pioneer of work intelligence and creator of the world's first Work Ontology®, has partnered with The Josh Bersin Company as the Trusted Content Partner for Galileo, the AI-powered HR expert assistant. Already trusted by global enterprises including WPP, Salesforce, Micron and IKEA, Reejig brings its detailed task-level intelligence to Galileo, giving leaders the most validated view of the work available today. Just like Google mapped the internet, Reejig has mapped work by breaking down every industry and role into its component tasks and skills. Built by world-leading workforce design experts, Reejig's Work Ontology® is powered by 23 proprietary industry ontologies, enriched with intelligence from over 130 million real jobs, and validated with billions of live work signals from the world's largest organizations - capturing the full DNA of how work is designed, executed, and evolved. This comprehensive mapping is what enables Reejig to deliver task-level intelligence - giving leaders visibility into exactly what work gets done and how it can be transformed. For Galileo, Reejig has provided its HR domain dataset, enabling leaders to see and understand the AI potential of all tasks in the HR function at a granular level of detail. Organizations looking to apply this same intelligence across finance, operations, technology, and every other function can access the full enterprise Work Ontology® directly through Reejig. The Clarity AI Transformation Has Been Missing As enterprises race to deploy AI, too many are doing so without a clear understanding of the work itself - risking wasted investment, workforce resistance, and misaligned priorities. The integration brings unprecedented task-level visibility into Galileo, enabling IT, HR, and business leaders to orchestrate AI transformation with precision — from identifying automation opportunities to re-engineering roles and reinventing work. With the Work Ontology®, leaders can: Gain complete visibility into every job, task, and process with clear, actionable data. Get the highest validated skill data by using skills based on the work being done, not inference. Plan AI transformation using work-level insights to identify automation opportunities, and work reinvention needs. Activate work intelligence to optimize resource allocation, maximize AI capabilities, and drive workforce efficiency. Siobhan Savage, CEO & Co-Founder of Reejig, said: "You can't lead an AI transformation if you can't see the work itself. Too many organizations are making AI decisions based on incomplete or outdated data, risking wasted investment and misaligned priorities. Our Work Ontology® is the critical infrastructure that makes work visible at the task level - so leaders know exactly what can be automated, what needs to evolve, and how to reinvent their workforces responsibly. By powering Galileo with this intelligence for HR, we're giving leaders the clarity, control, and confidence to redesign work for the AI era and do it at scale." Josh Bersin, CEO of The Josh Bersin Company, added: "Reejig's Work Ontology® turns Galileo into a "job task analysis" Agent instantly, helping HR and leadership teams quickly analyze job roles and find opportunities for AI transformation. We are excited to partner with Reejig, one of the leaders in AI-powered job task and work architecture tools." A New Standard for Work Intelligence Reejig's selection as the Trusted Content Partner for Galileo reinforces its position as the critical infrastructure for the AI-powered workforce. While Galileo now delivers unparalleled intelligence for HR work, the full scope of Reejig's Work Ontology® covers the entire enterprise - enabling organizations to apply the same level of precision to every function, from finance to operations to technology. By combining Reejig's granular, validated work data with Galileo's AI assistant and 25 years of Bersin research, enterprises gain the clarity, confidence, and control to: Scale AI initiatives without guesswork. Redesign roles and workflows with precision. Align talent, technology, and strategy to deliver measurable business impact. See It in Action Reejig and The Josh Bersin Company will be showcasing Galileo and Reejig live in action on September 4, 2025 in an exclusive webinar for enterprise leaders. Attendees will see how leaders can use this combined intelligence to redesign work, accelerate transformation, and unlock capacity. Register here: About Reejig Reejig is a force for workforce transformation in the AI era. Our Work Intelligence platform empowers organizations to boldly reinvent how work gets done, helping businesses thrive, individuals maximize their potential, and societies prosper. Through intelligent work orchestration, we're proving that AI isn't here to replace - it's here to empower. This is what we call Zero Wasted Potential. For more, go to About The Josh Bersin CompanyThe most trusted human capital advisors in the world. More than a million HR and business leaders rely on us to help them overcome their greatest people challenges. Thanks to our understanding of workplace issues, informed by the largest and most up-to-date data sets on workers and employees, we give leaders the confidence to make decisions in line with the latest thinking and evidence about work and the workplace. We're great listeners, too. There's no one like us, who understands this area so comprehensively and without bias. Our offerings include the industry's leading AI-powered HR expert assistant, Galileo®, fueled by 25 years of in-depth Josh Bersin Company research, case studies, benchmarks, and market information. We help CHROs and CEOs be better at delivering their business goals. We do that by helping you to manage people better. We are enablers at our core. We provide strategic advice and counsel supported by in-depth research, thought leadership, and unrivaled professional development, community, and networking opportunities. We empower our clients to run their businesses better. And we empower the market by identifying results-driven practices that make work better for every person on the planet. For more information, press only:Louisa Grundypress@ View original content to download multimedia: SOURCE Reejig
Business Wire
7 hours ago
- Business Wire
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's Aspirina, the #1 pain relief option in Mexico 1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic consumers, Aspirina is poised to provide an accessible and effective solution for pain relief. Bayer's Aspirina, the #1 pain relief option in Mexico, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. Share As the Hispanic population in the U.S. continues to grow, currently representing 19 percent of the population and projected to reach 28 percent by 2060, Bayer Aspirin recognizes the importance of connecting with this vibrant community. The Aspirina pain relief option resonates deeply with cultural values and family traditions of those from Mexican and Latin American descent who have been using it as a long-standing pain relief option. 'Many Hispanic communities still face inadequate access to healthcare and consumer goods. As the fastest-growing demographic group in the U.S., the Hispanic population presents a unique opportunity for Bayer. By adding Aspirina to the U.S. portfolio, which has a strong equity in LATAM, we are placing the consumer at the center of our strategy. Data shows that 70 percent of Hispanic consumers feel a strong connection to their country of origin, making it essential for brands to honor and reflect this sentiment,' said Mohamed Atef, Global Brand Lead for Aspirin at Bayer. Many U.S. consumers of Hispanic origin grew up with Bayer's Aspirina— their parents and grandparents relied on it, instilling trust and nostalgia for the brand. Due to those deep connections, Aspirina has a 99 percent awareness rate in Mexico, with 67 percent of consumers using it regularly 2. With this inclusion in the U.S. market, we invite consumers to reconnect with a product that represents reliability, familiarity and their heritage. Bayer invented modern aspirin 125 years ago, and it's the most trusted aspirin brand for pain relief in the U.S. 3 Many pain reliever brands have come and gone over the last century, but Bayer® Aspirin continues to be one of the most trusted pain brands on the market. Aspirina is available at select Walmart and Walgreens, making it easy for families to find the pain relief they know. Join us in celebrating the launch of Aspirina in the U.S. and rediscover a brand that feels like home — a trusted companion in the journey of life. For more information on Aspirina visit About Aspirina For over 125 years, Bayer® Aspirin has been a leading aspirin brand in proven pain relief. Aspirina is a powerful pain reliever and fever reducer that contains 500 mg of the active ingredient aspirin (NSAID*). It provides fast and effective multi-symptom relief of headaches, muscle pain, toothaches, menstrual pain and minor arthritis pain for adults and children over 12, when used as directed. Aspirina is coated to make it easy to swallow and is free of caffeine. *nonsteroidal anti-inflammatory drug About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 1 Based on volume sales in the last 52 weeks, via source: Grupo Knoblock/CID – Centro Integrador de Datos
